AnaptysBioの空売り状況は、投資家がAnaptysBioの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

AnaptysBio (NASDAQ:ANAB) 株価情報, 空売り情報

AnaptysBio

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

AnaptysBio Inc

<h3>Gainers</h3>
<ul>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares moved upwards by 29.7% to $19.5 during Friday's pre-market session. The market value of their outstanding shares is at $593.3 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock rose 25.88% to $0.09. The company's market cap stands at $1.4 million. </li>
<li>Channel Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) stock increased by 18.74% to $1.14. The company's market cap stands at $6.8 million. </li>
<li>Immuron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) stock moved upwards by 18.65% to $2.35. The company's market cap stands at $13.3 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) stock increased by 14.36% to $1.99. The company's market cap stands at $6.3 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares rose 13.66% to $1.83. The market value of their outstanding shares is at $21.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) shares fell 21.6% to $0.1 during Friday's pre-market session. The market value of their outstanding shares is at $12.7 million. </li>
<li>Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) stock declined by 17.78% to $0.31. The market value of their outstanding shares is at $1.5 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares declined by 12.29% to $0.15. The market value of their outstanding shares is at $11.9 million. </li>
<li>PureTech Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) shares decreased by 7.69% to $16.7. The market value of their outstanding shares is at $399.8 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock fell 7.17% to $3.11. The company's market cap stands at $2.1 million. </li>
<li>QT Imaging Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTI#NASDAQ">QTI</a>) shares declined by 6.88% to $0.49. The company's market cap stands at $10.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AEON

ANAB

BLRX

CHRO

GCTK

IMRN

MBRX

PRTC

RNAZ

SCPX

12 Health Care Stocks Moving In Friday's Pre-Market Session

JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Overweight and lowers the price target from $66 to $36.

News

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $36

AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for AnaptysBio, revealing an average target of $48.22, a high estimate of $90.00, and a low estimate of $20.00. Experiencing a 13.38% decline, the current average is now lower than the previous average price target of $55.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1734559231_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of AnaptysBio's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$20.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$66.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$52.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to AnaptysBio. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AnaptysBio compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of AnaptysBio's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of AnaptysBio's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ANAB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AnaptysBio analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind AnaptysBio</h2>
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
<h3>Financial Insights: AnaptysBio</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3 months period, AnaptysBio showcased positive performance, achieving a revenue growth rate of 804.67% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -109.44%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -69.71%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): AnaptysBio's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -7.14%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: AnaptysBio's debt-to-equity ratio is below the industry average at 0.2, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into AnaptysBio Stock: Analyst Perspectives (9 Ratings)

Truist Securities analyst John Lee maintains AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Hold and lowers the price target from $30 to $20.

Truist Securities Maintains Hold on AnaptysBio, Lowers Price Target to $20

Wells Fargo analyst Derek Archila maintains AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Overweight and lowers the price target from $56 to $40.

Wells Fargo Maintains Overweight on AnaptysBio, Lowers Price Target to $40

Guggenheim analyst Yatin Suneja maintains AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Buy and lowers the price target from $90 to $36.

Guggenheim Maintains Buy on AnaptysBio, Lowers Price Target to $36

<h3>Gainers</h3>
<ul>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) shares moved upwards by 172.2% to $12.55 during Wednesday's pre-market session. The company's market cap stands at $407.5 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock rose 34.75% to $0.53. The company's market cap stands at $5.3 million. </li>
<li>Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) stock moved upwards by 34.18% to $31.01. The market value of their outstanding shares is at $2.7 billion. As per the news, the Q2 earnings report came out 4 days ago. </li>
<li>Synlogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYBX#NASDAQ">SYBX</a>) stock increased by 17.3% to $1.7. The market value of their outstanding shares is at $19.8 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) stock moved upwards by 14.86% to $0.85. The company's market cap stands at $3.6 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares moved upwards by 14.71% to $2.65. The market value of their outstanding shares is at $7.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Q32 Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) shares declined by 67.0% to $8.05 during Wednesday's pre-market session. The market value of their outstanding shares is at $98.0 million. </li>
<li>Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) shares decreased by 66.41% to $0.43. The company's market cap stands at $17.7 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares declined by 36.51% to $14.66. The market value of their outstanding shares is at $446.0 million. </li>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) shares declined by 33.88% to $0.2. </li>
<li>ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) stock declined by 28.24% to $3.33. The market value of their outstanding shares is at $2.3 billion. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock fell 26.93% to $0.46. The market value of their outstanding shares is at $3.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPTH

CADL

CLRB

HEPA

IBRX

NIVF

PDCO

QTTB

SYBX

TFFP

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

WIIM

AnaptysBio shares are trading lower after the company announced it will discontinue its ANB023 development after its Phase 2b trial in atopic dermatitis failed to meet its endpoints. Also, HC Wainwright & Co. downgraded the stock from Buy to Neutral.

On Wednesday, AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42436193/anaptys-announces-phase-2b-trial-of-anb032-a-btla-agonist-did-not-meet-primary-or-secondary-endpoi" rel="noreferrer noopener">(AD) or eczema</a>.
&#8220;While ANB032 was safe and well tolerated, we&#8217;re disappointed by these efficacy results in AD and will discontinue further investment in this asset. Moving forward, our resources and capital will be focused on the rest of our exciting autoimmune portfolio,&#8221; said Daniel Faga, president and chief executive officer of Anaptys.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39891711/anaptysbio-investigational-arthritis-drug-might-have-better-efficacy-profile-than-eli-lillys-anal" rel="noreferrer noopener">AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly&#8217;s: Analyst</a>
&#8220;We look forward to sharing for rosnilimab, a depleter and agonist targeting PD-1+ T cells, top-line Phase 2b rheumatoid arthritis data in February 2025 and top-line Phase 2 ulcerative colitis data in Q1 2026, followed by Phase 1b data from our two additional programs.&#8221;
The study enrolled 201 patients with a mean baseline EASI score of 27.3 in the U.S., Canada, Europe, Australia and New Zealand, who were either biologics naïve (n=168) or biologics experienced (n=33), defined as having received treatment with dupilumab or other IL-13 therapies.
Patients were randomized to receive either 100mg of subcutaneous ANB032 every four weeks (Q4W), 400mg every four weeks (Q4W), 400mg every two weeks (Q2W), or placebo for 12 weeks.
The primary and secondary endpoints were assessed at Week 14.
Regardless of prior treatment experience, ANB032 did not meet the primary endpoint of the proportion of patients who achieved at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI-75), or any of the secondary endpoints at Week 14, including EASI-90, mean change in baseline EASI or a 4-point reduction in itch severity versus placebo.
Absolute response rates on key endpoints in patients treated with ANB032 approached the minimum target product profile with durable off-drug responses; however, higher placebo rates outside of the historical norm, particularly in the U.S., were observed.
ANB032 was well tolerated across all doses, and no safety signals were observed.
Price Action: ANAB stock is down 36.3% at $14.72 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/12/42439950/dental-product-supplier-patterson-companies-goes-private-in-4-1-billion-deal" target="_blank" rel="noreferrer noopener">Dental Product Supplier Patterson Companies Goes Private In $4.1 Billion Deal</a></li>
</ul>

Biotech

Health Care

Trading Ideas

General

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

HC Wainwright &amp; Co. analyst Emily Bodnar downgrades AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) from Buy to Neutral.

Downgrades

HC Wainwright & Co. Downgrades AnaptysBio to Neutral

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Anaptys Discontinues ANB032 Development After Phase 2b Trial In Atopic Dermatitis Fails To Meet Endpoints; Focus Shifts To Rosnilimab Data In Rheumatoid Arthritis Expected February 2025; Year-End Cash Of $415M Extends Runway Through 2027

Trading Halt: Halted at 8:25:00 a.m. ET - Trading Halt: Halt News Pending

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $56.33, along with a high estimate of $90.00 and a low estimate of $33.00. This upward trend is apparent, with the current average reflecting a 3.99% increase from the previous average price target of $54.17.
<img src="https://www.benzinga.com/files/images/story/2024/1733162467_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of AnaptysBio among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$66.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$52.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AnaptysBio. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of AnaptysBio compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for AnaptysBio's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into AnaptysBio's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ANAB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AnaptysBio analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About AnaptysBio</h2>
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
<h3>AnaptysBio: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: AnaptysBio's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 804.67%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -109.44%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): AnaptysBio's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -69.71%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -7.14%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.2, AnaptysBio adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From AnaptysBio Analyst Ratings

AnaptysBio shares are trading lower after BTIG downgraded the stock from Buy to Neutral.

BTIG analyst Julian Harrison downgrades AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) from Buy to Neutral.

BTIG Downgrades AnaptysBio to Neutral

JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Overweight and lowers the price target from $75 to $66.

JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $66

HC Wainwright &amp; Co. analyst Emily Bodnar maintains AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Buy and lowers the price target from $55 to $52.

HC Wainwright & Co. Maintains Buy on AnaptysBio, Lowers Price Target to $52

AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) reported quarterly losses of $(1.14) per share which beat the analyst consensus estimate of $(1.65) by 30.91 percent. This is a 19.15 percent increase over losses of $(1.41) per share from the same period last year. The company reported quarterly sales of $30.02 million which beat the analyst consensus estimate of $6.87 million by 336.74 percent. This is a 804.67 percent increase over sales of $3.32 million the same period last year.

Earnings

Earnings Beats

AnaptysBio Q3 EPS $(1.14) Beats $(1.65) Estimate, Sales $30.02M Beat $6.87M Estimate

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Buy and maintains $55 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $55 Price Target

Derek Archila, an analyst from Wells Fargo, assigned the Buy rating on AnaptysBio (ANAB – Research Report). The associated price target is $40.00. ...

Buy Rating on AnaptysBio: Strategic Focus on Rosnilimab Amidst Stock Valuation Opportunity

Guggenheim lowered the firm's price target on AnaptysBio (ANAB) to $36 from $90 and keeps a Buy rating on the shares following the announcement tha...

AnaptysBio price target lowered to $36 from $90 at Guggenheim

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Adobe (ADBE) reported better-than-expe...

Adobe outlook disappoints, Kroger announces $7.5B buyback: Morning Buzz

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Broadcom (AVGO) jumped as enthusiasm a...

Broadcom tops $1T market cap on AI enthusiasm: Morning Buzz

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Keros Therapeutics (KROS – Research Report), Anaptys...

Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), AnaptysBio (ANAB) and US Physical Therapy (USPH)

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on AnaptysBio (ANAB – Research Report) yesterday and set a price target of $41.00...

Stifel Nicolaus Sticks to Their Buy Rating for AnaptysBio (ANAB)

Truist lowered the firm's price target on AnaptysBio (ANAB) to $20 from $30 and keeps a Hold rating on the shares. The firm is removing ANB032 in a...

AnaptysBio price target lowered to $20 from $30 at Truist

AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout

JPMorgan lowered the firm's price target on AnaptysBio (ANAB) to $36 from $66 and keeps an Overweight rating on the shares. The firm says sentiment...

AnaptysBio price target lowered to $36 from $66 at JPMorgan

ADBE

AFRM

AMZN

AUPH

AVGO

BGNE

CHTR

CIEN

CMCSA

CMRX

COST

ELVA

EVGO

EYEN

HNDAF

JAGX

KROS

KVUE

LOVE

NDSN

NFLX

NVDA

PENN

QURE

SCHW

SFIX

SNYNF

SSNLF

TASK

TMUS

USPH

VWAGY

VWAPY

XFOR

Contracts

Press Releases

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Anaptys Announces Participation in September Investor Conferences

Anaptys Announces Participation in November and December Investor Conferences

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Comments

AnaptysBio

空売り

AnaptysBio (NASDAQ:ANAB) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル